An advisory panel has answered in no uncertain terms the US Food and Drug Administration’s question on whether research supports the efficacy of one of the most commonly used OTC nasal decongestants, oral phenylephrine.
Should the agency act on the unanimous statement the Nonprescription Drug Advisory Committee made on 12 September, it could be in one of its first use of additional tools in its more streamlined process for making OTC monograph changes by removing the